Cardiotoxicity associated with PD-1 blocking therapy

doi:10.3877/cma.j.issn.2095-3224.2017.05.011

Abstract

Abstract:

PD-1 checkpoint blocking has been demonstrated objective efficacy in dMMR colorectal tumors, meanwhile more attention has been focused on immune-related adverse event. As hypothyroidism, hyperthyroidism and pruritus are most frequent compared to standard of care approaches have been reported, it should be emphasized that whether serious adverse reactions could affects the prognosis severely in immune treatment while we maximize the curative effect. This review summarizes the cardiotoxicity associated with PD-1 blocking therapy.

Key words: Colorectal neoplasms, Side effect, PD-1 blocking, Cardiac, Immunotherapy

Ling Qi, Jing Huang. Cardiotoxicity associated with PD-1 blocking therapy[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(05): 407-409.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.05.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/407

References 19

[1]	Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4):252-264.
[2]	Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nature Med, 1999, 5(12), 1365-1369.
[3]	Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nature Med, 2002, 8(8), 793–800.
[4]	Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1(B7-H1) augments human tumor-specific T cell responses in vitro[J]. Int J Cancer, 2006, 119(2):317-327.
[5]	Costa R, Carneiro BA, Agulnik M, et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials[J]. Oncotarget, 2017, 8(5):8910-8920.
[6]	Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy[J]. J Immunother Cancer, 2016, 16(4):50.
[7]	Läubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma[J]. J Immunother Cancer, 2015, 21(3):11.
[8]	Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60(6):210-225.
[9]	Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies[J]. N Engl J Med, 2016, 375(15):1457-1467.
[10]	Grabie N, Gotsman I, DaCosta R, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8⁺ T-cell mediated injury in the heart[J]. Circulation, 2007, 116(18):2062-2071.
[11]	Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis[J]. J Immunol, 2012, 188(10):4876-4884.
[12]	Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice[J]. Science, 2001, 291(5502):319-322.
[13]	Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice[J]. Nat Med, 2003, 9(12):1477-1483.
[14]	Goser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune in- flammation in the myocardium[J]. Circulation, 2006, 114(16):1693.
[15]	Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application[J]. Int Immunol, 2007, 19(7):813-824.
[16]	Lucas JA, Menke J, Rabacal WA, et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice[J]. J Immunol, 2008, 181(4):2513-2521.
[17]	Wang J, Okazaki IM, Yoshida T, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice[J]. Int Immunol, 2010, 22(6):443-452.
[18]	Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines[J]. European Heart Journal, 2016, 37(36):2768-2801.
[19]	Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, et al. Takotsubo cardiomyopathy-the current state of knowledge[J]. Int J Cardiol, 2010, 142(2):120-125.

Please choose a citation manager

Content to export